{"id":"68ga-dotatoc","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure (minimal; diagnostic dose)"},{"rate":null,"effect":"Allergic reaction to peptide"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1791313","moleculeType":"Small molecule","molecularWeight":"1491.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DOTATOC is a somatostatin receptor-targeting peptide conjugated to gallium-68, a positron-emitting radioisotope. The peptide binds with high affinity to somatostatin receptor subtype 2 (SSTR2) and other somatostatin receptors expressed on neuroendocrine tumors. The gallium-68 radiolabel allows real-time visualization of tumor location and burden via PET imaging, facilitating diagnosis, staging, and treatment planning.","oneSentence":"68Ga-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, enabling their detection and localization via positron emission tomography (PET) imaging.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:01.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of somatostatin receptor-positive neuroendocrine tumors (NET)"},{"name":"Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"},{"name":"Neuroendocrine tumor detection and staging"}]},"trialDetails":[{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":"ACTH, Cushing's Syndrome","enrollment":80},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":"Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT00001160","phase":"","title":"Studies on Tumors of the Thyroid","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1977-06-01","conditions":"Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer, Follicular Thyroid Cancer","enrollment":2500},{"nctId":"NCT04804371","phase":"NA","title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-04","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT04927416","phase":"PHASE2","title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-10-25","conditions":"Metastic Thyroid Cancer","enrollment":54},{"nctId":"NCT07472049","phase":"","title":"Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-07-31","conditions":"Peripheral Arterial Disease, Chronic Limb Threatening Ischemia","enrollment":100},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT06427798","phase":"PHASE1, PHASE2","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-07","conditions":"Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma","enrollment":66},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":"Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":15},{"nctId":"NCT04298541","phase":"PHASE2","title":"Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-06","conditions":"Meningioma","enrollment":6},{"nctId":"NCT04074135","phase":"PHASE2","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-02","conditions":"VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors","enrollment":740},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":"Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors","enrollment":130},{"nctId":"NCT07178587","phase":"NA","title":"Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02-02","conditions":"Hepatocellular Carcinoma (HCC), Gastro-Entero-Pancreatic Tumors (GEPs)","enrollment":28},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":"Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT07366099","phase":"NA","title":"Al18F-NOTA-LM3 PET/CT in Patients With TIO","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-03-30","conditions":"Tumor-Induced Osteomalacia","enrollment":40},{"nctId":"NCT07353229","phase":"PHASE1","title":"68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma","status":"SUSPENDED","sponsor":"Thomas Jefferson University","startDate":"2025-09-05","conditions":"High Risk Meningioma, Recurrent Meningioma","enrollment":24},{"nctId":"NCT07350707","phase":"PHASE1, PHASE2","title":"Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-06-12","conditions":"Cushing s Syndrome","enrollment":160},{"nctId":"NCT04040088","phase":"EARLY_PHASE1","title":"An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-23","conditions":"Ganglioneuroblastoma, Ganglioneuroma, Neuroblastoma","enrollment":20},{"nctId":"NCT07150806","phase":"PHASE1, PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":"Recurrent Meningioma","enrollment":30},{"nctId":"NCT07288931","phase":"NA","title":"Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-06","conditions":"Pheochromocytoma/Paraganglioma (PPGL)","enrollment":40},{"nctId":"NCT07284589","phase":"PHASE2","title":"Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake","status":"RECRUITING","sponsor":"Akiva Mintz","startDate":"2025-12-11","conditions":"Healthy (Controls), Healthy Volunteers, Neuroendocrine (NE) Tumors","enrollment":200},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":"Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma","enrollment":41},{"nctId":"NCT04069299","phase":"","title":"Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-25","conditions":"Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT02743741","phase":"NA","title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-07-15","conditions":"Neuroendocrine Tumors","enrollment":195},{"nctId":"NCT06479811","phase":"PHASE1","title":"[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-19","conditions":"Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers","enrollment":120},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":10},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":30},{"nctId":"NCT06256705","phase":"NA","title":"Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-25","conditions":"Gastroenteropancreatic Neuroendocrine Tumor, Radiotherapy","enrollment":80},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":"Neuroendocrine Tumors","enrollment":300},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT07119242","phase":"PHASE3","title":"Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2024-01-08","conditions":"NETs","enrollment":95},{"nctId":"NCT01879657","phase":"NA","title":"68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)","status":"COMPLETED","sponsor":"Radio Isotope Therapy of America","startDate":"2013-03-01","conditions":"Neuroendocrine Carcinoma","enrollment":169},{"nctId":"NCT03448458","phase":"PHASE2","title":"Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-22","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7","enrollment":17},{"nctId":"NCT03576040","phase":"","title":"Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2018-07-19","conditions":"Neuroendocrine Tumors","enrollment":120},{"nctId":"NCT03583528","phase":"","title":"DOTATOC PET/CT for Imaging NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2018-07-11","conditions":"Neuroendocrine Tumors, Insulinoma, Gastrinoma","enrollment":800},{"nctId":"NCT06091748","phase":"PHASE3","title":"Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02-22","conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":66},{"nctId":"NCT06455358","phase":"PHASE1, PHASE2","title":"61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-02-05","conditions":"Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT02840149","phase":"PHASE3","title":"SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2019-10-01","conditions":"Neuroendocrine Tumors","enrollment":45},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":"Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors","enrollment":10},{"nctId":"NCT03736564","phase":"PHASE1, PHASE2","title":"Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-01-31","conditions":"Osteomalacia","enrollment":18},{"nctId":"NCT06800430","phase":"","title":"Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-28","conditions":"Coronary Artery Bypass, Graft Failure, Coronary Artery Bypass Graft","enrollment":70},{"nctId":"NCT06056362","phase":"PHASE1, PHASE2","title":"Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-03-23","conditions":"Neuroendocrine Tumors","enrollment":80},{"nctId":"NCT03602911","phase":"PHASE2","title":"A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2019-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT06611891","phase":"PHASE3","title":"Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2025-01-06","conditions":"Breast Cancer Metastatic","enrollment":25},{"nctId":"NCT06773624","phase":"NA","title":"Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2021-04-23","conditions":"Small Bowel Neoplasia, Neuroendocrine (NE) Tumors","enrollment":18},{"nctId":"NCT06188468","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-10-01","conditions":"Tumor, Solid Tumor, Positron-Emission Tomography","enrollment":90},{"nctId":"NCT05183555","phase":"PHASE2","title":"Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2022-05-16","conditions":"Infective Endocarditis","enrollment":14},{"nctId":"NCT04559217","phase":"PHASE2","title":"68Ga-DOTATATE Neuroblastoma Imaging Pilot","status":"RECRUITING","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2021-12-06","conditions":"Neuroblastoma","enrollment":20},{"nctId":"NCT06520319","phase":"PHASE1","title":"Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2023-06-21","conditions":"Medullary Thyroid Carcinoma","enrollment":20},{"nctId":"NCT06226987","phase":"","title":"Molecular Imaging in Fabry Disease of the Heart","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2024-01-02","conditions":"Fabry Disease, Cardiac Variant","enrollment":12},{"nctId":"NCT01873248","phase":"EARLY_PHASE1","title":"Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2013-08-26","conditions":"Neuroendocrine Tumors","enrollment":100},{"nctId":"NCT04073797","phase":"NA","title":"PET Imaging of Inflammation and Lipid Lowering Study","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2023-03-20","conditions":"Hypercholesterolemia, Hypercholesterolemia, Familial, Atherosclerosis","enrollment":63},{"nctId":"NCT04073810","phase":"","title":"Residual Inflammation and Plaque Progression Long-term Evaluation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2020-10-01","conditions":"Atherosclerosis, Myocardial Infarction, Coronary Artery Disease","enrollment":40},{"nctId":"NCT04412369","phase":"","title":"Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2020-07-01","conditions":"COVID19, Cardiovascular Diseases","enrollment":21},{"nctId":"NCT04847505","phase":"PHASE3","title":"68Ga-DOTA-TATE PET/CT Imaging in NETs","status":"RECRUITING","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2020-01-01","conditions":"Neuroendocrine Tumors","enrollment":5000},{"nctId":"NCT06467968","phase":"NA","title":"Heart Analysis in GATED-PET in Patients Having a Gallium-68-DOTATOC PET/CT Exam for Oncology Indication","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2023-02-02","conditions":"Cardiac Inflammation","enrollment":99},{"nctId":"NCT05478733","phase":"","title":"Study of Factors Associated With Significant MYoCArdian Uptake on 68Ga-DOTATOC PET Scans for Oncology","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2022-09-01","conditions":"Oncologic Disorders","enrollment":210},{"nctId":"NCT06359054","phase":"NA","title":"The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging","status":"COMPLETED","sponsor":"Celal Bayar University","startDate":"2020-11-11","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT06159920","phase":"","title":"Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2021-10-27","conditions":"Neuroendocrine Tumors","enrollment":800},{"nctId":"NCT05069220","phase":"EARLY_PHASE1","title":"18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-01","conditions":"Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma","enrollment":150},{"nctId":"NCT05990998","phase":"PHASE1, PHASE2","title":"A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2022-11-20","conditions":"Tumor Positron-Emission Tomography","enrollment":38},{"nctId":"NCT05536960","phase":"NA","title":"Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-09-09","conditions":"Atheroscleroses, Coronary","enrollment":41},{"nctId":"NCT03347760","phase":"NA","title":"Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-07-13","conditions":"Myocarditis","enrollment":33},{"nctId":"NCT03873870","phase":"NA","title":"68Ga-DOTATATE PET for Management of Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-03-28","conditions":"Neuroendocrine Tumors","enrollment":1916},{"nctId":"NCT06155318","phase":"","title":"68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2019-09-05","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":300},{"nctId":"NCT04040166","phase":"NA","title":"Carotid PET/MRI With DOTATATE in Patients Post Head and Neck Radiation Therapy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-08-22","conditions":"Head & Neck Cancer","enrollment":20},{"nctId":"NCT05448157","phase":"","title":"68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2022-05-12","conditions":"Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net","enrollment":20},{"nctId":"NCT03623984","phase":"EARLY_PHASE1","title":"Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2019-06-07","conditions":"Neuroendocrine Carcinoma of Pancreas, Carcinoid","enrollment":""},{"nctId":"NCT03953131","phase":"PHASE1","title":"Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-10","conditions":"Meningioma","enrollment":13},{"nctId":"NCT03136328","phase":"PHASE3","title":"Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2016-05-16","conditions":"Neuroendocrine Tumors","enrollment":11},{"nctId":"NCT02150408","phase":"NA","title":"Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2014-04-22","conditions":"Gastro-Entero-Pancreatic Tumors (GEPs)","enrollment":35},{"nctId":"NCT02186678","phase":"NA","title":"Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2014-07-18","conditions":"Paragangliomas, Pheochromocytomas","enrollment":30},{"nctId":"NCT05730634","phase":"NA","title":"The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-06-01","conditions":"Diabetes Mellitus, Type 2, Vascular Inflammation","enrollment":24},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":"Neuroendocrine Tumors, Meningioma, Neuroblastoma","enrollment":39},{"nctId":"NCT03648073","phase":"PHASE1, PHASE2","title":"[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-01-30","conditions":"Hepatocellular Carcinoma","enrollment":12},{"nctId":"NCT03478358","phase":"PHASE1","title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":"Neuroendocrine Tumors","enrollment":60},{"nctId":"NCT04043377","phase":"PHASE3","title":"68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-21","conditions":"Coronary Arteriosclerosis","enrollment":12},{"nctId":"NCT00001277","phase":"PHASE2","title":"Studies of Elevated Parathyroid Activity","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1993-12-15","conditions":"Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm","enrollment":1553},{"nctId":"NCT03741517","phase":"","title":"Biomarker Study of Pancreatic Neuroendocrine Tumours","status":"UNKNOWN","sponsor":"Uppsala University","startDate":"2019-01-30","conditions":"Pancreatic Neuroendocrine Tumor","enrollment":40},{"nctId":"NCT01869725","phase":"PHASE2","title":"Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2013-04-01","conditions":"Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma","enrollment":68},{"nctId":"NCT01619865","phase":"PHASE1, PHASE2","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2012-02-21","conditions":"Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma","enrollment":223},{"nctId":"NCT03125629","phase":"PHASE2","title":"Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-05-27","conditions":"Cancer Diagnosis, Diagnostic Techniques and Procedures, Diagnostic Imaging","enrollment":53},{"nctId":"NCT03001349","phase":"EARLY_PHASE1","title":"68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-16","conditions":"Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1","enrollment":4},{"nctId":"NCT04017104","phase":"","title":"Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2019-11-01","conditions":"Neuroendocrine Tumors, Prostate Cancer, Prostatic Neoplasms","enrollment":60},{"nctId":"NCT04689893","phase":"PHASE1","title":"Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-15","conditions":"Tumor-Induced Osteomalacia","enrollment":50},{"nctId":"NCT02441062","phase":"PHASE2","title":"Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2015-09","conditions":"Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma","enrollment":122},{"nctId":"NCT04622631","phase":"","title":"Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT","status":"UNKNOWN","sponsor":"Dr. Nayruz Knaana","startDate":"2020-11","conditions":"Neuroendocrine Tumors","enrollment":80},{"nctId":"NCT03549598","phase":"PHASE4","title":"d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-07-20","conditions":"Cardiac Sarcoidosis","enrollment":15},{"nctId":"NCT02174679","phase":"","title":"68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)","status":"NO_LONGER_AVAILABLE","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"","conditions":"Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer","enrollment":""},{"nctId":"NCT03197012","phase":"EARLY_PHASE1","title":"Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Thomas Hope","startDate":"2017-07-01","conditions":"Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT01967537","phase":"PHASE2","title":"Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-18","conditions":"Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease","enrollment":341},{"nctId":"NCT02177773","phase":"PHASE1, PHASE2","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-06-23","conditions":"Neuroendocrine Tumor, Paraganglioma, Carcinoid Tumors","enrollment":300},{"nctId":"NCT04152928","phase":"NA","title":"Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-02-25","conditions":"Neuroendocrine Tumors","enrollment":50},{"nctId":"NCT04041882","phase":"EARLY_PHASE1","title":"68Ga-DOTATATE PET/CT in Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-04-01","conditions":"Neuroendocrine Tumors","enrollment":100},{"nctId":"NCT03057509","phase":"PHASE1","title":"A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-11","conditions":"Small Bowel Carcinoid Tumor","enrollment":""},{"nctId":"NCT03013387","phase":"PHASE2","title":"Dosimetry Guided PRRT With 90Y-DOTATOC","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2017-01","conditions":"Neuroendrocrine Tumors, Meningioma, Neuroblastoma","enrollment":""},{"nctId":"NCT01980732","phase":"","title":"68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors","status":"NO_LONGER_AVAILABLE","sponsor":"Andrei Iagaru","startDate":"","conditions":"Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT02134639","phase":"","title":"PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-09","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT02359500","phase":"PHASE1","title":"68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)","status":"TERMINATED","sponsor":"Lale Kostakoglu","startDate":"2014-12","conditions":"Neuroendocrine Tumors, Carcinoid Tumors","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diagnostic test"],"phase":"phase_3","status":"active","brandName":"68Ga-DOTATOC","genericName":"68Ga-DOTATOC","companyName":"Montefiore Medical Center","companyId":"montefiore-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"68Ga-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, enabling their detection and localization via positron emission tomography (PET) imaging. Used for Imaging of somatostatin receptor-positive neuroendocrine tumors (NET), Gastroenteropancreatic neuroendocrine tumors (GEP-NET), Neuroendocrine tumor detection and staging.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}